Drug Detail

Information about Ripretinib plus Binimetinib

Generic Name	Ripretinib plus Binimetinib
IND
Brand Name (US)
Manufacturer	Deciphera / Array
Drug Type
Delivery	Oral
Approval Status
Indications
Overall Strategy	KIT Protein Based + Oncogenic Signal Path Based
Strategy	Block KIT + Block related tumor signal paths
Drug Category	KIT/PDGFRA inhibitor + MEK inhibitor

Links
Trials of this drug
	Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Trial results